- 24 h
- 7 Tage
- 14 Tage
- 6 Monate
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18:36 | Regeneron-Licensed Obesity Drug Olatorepatide Shows Positive Results In Phase 3 Trial | 45 | AFX News | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals said olatorepatide, an investigational obesity treatment it licensed from Hansoh Pharmaceutical Group, delivered positive Phase 3 trial results... ► Artikel lesen | |
| 18:36 | enGene Holdings GAAP EPS of $0.44 | 1 | Seeking Alpha | ||
| 18:30 | Baird raises Xenon Pharmaceuticals price target to $97 on trial data | 1 | Investing.com | ||
| 18:30 | Baird reiterates Dyne Therapeutics stock rating on trial progress | 1 | Investing.com | ||
| 18:29 | Regeneron-Licensed Obesity Drug Olatorepatide Shows Positive Results In Phase 3 Trial | 3 | RTTNews | ||
| 18:29 | Precision BioSciences Gets FDAT Fast Track Status For PBGENE-DMD | 3 | RTTNews | ||
| 18:10 | TD Cowen bestätigt Kaufempfehlung für Editas Medicine nach Pipeline-Fortschritten | 3 | Investing.com Deutsch | ||
| 18:10 | H.C. Wainwright senkt Kursziel für Olema Pharmaceuticals nach Studiendaten | 5 | Investing.com Deutsch | ||
| 18:06 | GENFIT S.A.: GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF | 3 | GlobeNewswire (Europe) | FDA grants Orphan Drug Designation (ODD) for NTZ for ACLF, a severe condition with no approved therapiesNTZ is being advanced in ACLF through its G1090N reformulation, designed to unlock its clinical... ► Artikel lesen | |
| 18:06 | TD Cowen reiterates Editas Medicine stock Buy rating on pipeline progress | 1 | Investing.com | ||
| 18:06 | H.C. Wainwright cuts Olema Pharmaceuticals price target on trial data | 1 | Investing.com | ||
| 18:06 | MaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD Management | 113 | Business Wire |
Oral presentation during Presidential Plenary Session to feature the final results of the ARES pivotal Phase 3 trial evaluating MaaT013 in acute Graft-versus-Host Disease (aGvHD) with gastrointestinal... ► Artikel lesen | |
| 17:59 | Xenon Pharmaceuticals Shares Surge 48% On Strong Phase 3 Epilepsy Trial Results | - | RTTNews | ||
| 17:59 | Korro Bio Shares Rise 10% After Announcing $85 Mln PIPE Financing | - | RTTNews | ||
| 17:55 | TRADING UPDATES: Genedrive raises extra funds through subscription | 1 | Alliance News | ||
| 17:54 | Dianthus Therapeutics stock maintained at Buy by TD Cowen | 2 | Investing.com | ||
| 17:54 | Jones Trading reiterates Buy on Dyne Therapeutics stock after DMD, DM1 updates | 1 | Investing.com | ||
| 17:51 | Valneva SE - 6-K, Report of foreign issuer | 11 | SEC Filings | ||
| 17:48 | Valneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026 | 15 | GlobeNewswire (USA) | ||
| 17:46 | UniQure leads genetic medicine biotech rally after news of Prasad's exit | 2 | BioPharma Dive |
1 2 3 4 5 Weiter >>
- 24 h
- 7 Tage
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | Aktuelle Nachrichten | |||
|---|---|---|---|---|---|---|---|
| DIANTHUS THERAPEUTICS | 24 | - | +19,47 % | Dianthus Therapeutics, Inc.: Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results | Early GO decision reached in CAPTIVATE ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Phase 3... ► Artikel lesen | ||
| XENON PHARMACEUTICALS | 19 | - | +47,22 % | XFRA XP0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILXENON PHARMACEUTICALS... ► Artikel lesen | ||
| DYNE THERAPEUTICS | 11 | - | +16,21 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) | - HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for enrollment... ► Artikel lesen | ||
| REGENERON PHARMACEUTICALS | 8 | 22 | +1,68 % | Regeneron Pharmaceuticals, Inc.: Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients | Patients treated with olatorepatide achieved up to 19% body-weight loss at week 48 Regeneron's global Phase 3 registrational program to be initiated later this year TARRYTOWN, N.Y., March 09, 2026... ► Artikel lesen | ||
| RELMADA THERAPEUTICS | 7 | - | +47,14 % | Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer | Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any time Tolerability... ► Artikel lesen | ||
| KORRO BIO | 7 | - | +10,29 % | Korro announces oversubscribed $85 million private placement | |||
| EVOTEC | 6 | 44 | -3,55 % | Biotech rückt wieder in den Fokus - Mesoblast und BioNTech im Blick | |||
| NEWCELX | 6 | 4 | +3,91 % | NewcelX Ltd.: NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes | Collaboration Integrates Stem-Cell-Derived Islets with Targeted Immune Modulation
ZURICH, Switzerland, March 9, 2026 /PRNewswire/ -- NewcelX Ltd. ("NewcelX") (Nasdaq:... ► Artikel lesen | ||
| BIOMX | 6 | 2 | +16,37 % | Biomx Ltd.: BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth | Seasoned financial leaders join BiomX to support strategic execution and advancement of the company
DOVER, Del. and NESS ZIONA, Israel, March 9, 2026 /PRNewswire/... ► Artikel lesen | ||
| ARS PHARMACEUTICALS | 6 | - | +1,87 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy (epinephrine nasal spray) Commercialization | neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.